OncoMatch/Clinical Trials/NCT03832127
Evaluation of PET 18F-Fludarabine for the Initial Assessment and End-treatment of Symptomatic Multiple Myeloma Patients
Is NCT03832127 recruiting? Yes, currently enrolling (May 2026). This Phase 1 trial studies 18F-Fludarabine for myeloma.
Treatment: 18F-Fludarabine — The objective of this exploratory study is to evaluate, for the first time, the sensitivity of 18F-Fludarabine to the initial diagnosis of MM compared to FDG-PET and MRI. The interest of this molecule will also be investigated as part of the end-of-treatment therapeutic evaluation.
Check if I qualifyExtracted eligibility criteria
Cancer type
Multiple Myeloma
Performance status
KARNOFSKY/ECOG 0–1
Karnofsky ≥ 70 or ECOG 0-1
Prior therapy
Lab requirements
Blood counts
neutropenia < 1000 PN/mm3; thrombocytopenia < 70,000/mm3 [excluded]
Kidney function
creatinine clearance < 50 ml/min [excluded]
Liver function
bilirubin > 35μmol/L and SGOT, SGPT, alkaline phosphatase greater than 3 N [excluded]
Neutropenia <1000 PN / mm3; Thrombocytopenia <70,000 / mm3; Hepatic impairment: bilirubin> 35μmol / L and SGOT, SGPT, alkaline phosphatase greater than 3 N; Renal impairment defined by creatinine clearance <50 ml / min
Structured fields extracted by AI. May contain errors — verify against the official protocol.
Could you qualify for this trial?
Enter your biomarker results to see how this trial's eligibility criteria match your specific cancer profile.
Check if I qualify